Статья
ДЕФИЦИТ ВИТАМИНА D И АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ: ЧТО ОБЩЕГО?
Настоящий обзор посвящен оценке современных представлений о взаимосвязях между дефицитом витамина D и артериальной гипертензией (АГ) и включает в себя результаты оригинальных отечественных и зарубежных исследований, проспективных наблюдений, а также данных метаанализов. В работе представлены возможные механизмы развития кардиоваскулярной патологии в условиях дефицита витамина D и носительства различных полиморфизмов гена рецептора витамина D. Отдельно проанализированы данные о влиянии терапии препаратами витамина D на уровень артериального давления и риск развития АГ. Информация, представленная в данном обзоре, позволит расширить представление о патогенетических механизмах развития АГ и будет интересна специалистам широкого профиля.
1. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.
2. Пигарова Е. А., Рожинская Л. Я., Белая Ж. Е., Дзеранова Л. К., Каронова Т. Л., Ильин А. В. и др. Клинические рекомендации российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016;62(4):60–84..
3. Pilz S, Tomaschitz A, Ritz E, Pieberet TR. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol. 2009;6(10):621–30. doi:10.1038/nrcardio.2009.135.
4. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49 (5):1063–9.
5. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52(5):828–32. doi:10.1161/ HYPERTENSIONAHA.108.117630
6. Porrecca E, Di Febbo C, Fusco L, Moretta V, Di Nisio M, Cuccurullo F. Solube thrombomodulin and vascular adhesion molecule-1 are associeted to leptin plasma levels in obese women. Atherossclerosis. 2004;172(1):175–80.
7. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14. doi:10.7326/0003–4819– 152–5-201003020–00009
8. Forouhi NG, Luan J, Cooper A, Boucer BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes. 2008;57 (10):2619–25. doi:10.2337/db08–0593
9. Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but not predict futurehypertension. Hypertension. 2010;55(3):792–8. doi:10.1161/HYPERTENSIONAHA.109. 143990
10. Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif. Tissue Int. 1987;41(2):112–4.
11. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O et al. 25-hydroxyvitamin D3–1-alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;111(13):1666–71.
12. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11. doi:10.1161/CIRCULATIONAHA.107.706127
13. Motiwala SR, Wang TJ. Vitamin D and cardiovascular disease. Curr Opin Nephrol. Hypertens. 2011;20(4):345–53. doi:10.1097/MNH.0b013e3283474985
14. Abu el Maaty MA, Gad MZ. Vitamin D deficiency and cardiovascular disease: potential mechanisms and novel perspectives. J Nutr Sci Vitaminol (Tokyo). 2013;59(6):479–88.
15. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3: specific inhibition at the level of messenger RNA. J Clin Invest. 1987;79(6):1659–64.
16. O’Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25-dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol. 1997;272 (4 Pt 2): H1751–8.
17. Li YC, Kong J, Wei MJ, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D (3) is a negative endocrine regulator of renin-angiotensin system. Clin Invest. 2002;110(2):229–38.
18. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; 369(9568):1208–19.
19. Асташкин Е. И., Глезер М. Г. Новые данные о функционировании ренин-ангиотензиновой системы: роль внутриклеточной (интракринной) системы. Проблемы женского здоровья. 2012;7(4):47–54..
20. Баженова Е. А., Беляева О. Д., Березина А. В., Каронова Т. Л., Колодина Д. А., Бровин Д. Л. и др. Ренин-ангиотензинальдостероновая система у больных абдоминальным ожирением и артериальной гипертензией. Артериальная гипертензия. 2013;19(5):389–96..
21. Bugress ED, Hawkins RG, Vatanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens. 1990;3(12 Pt 1):903–5.
22. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W et al. Cardiac hypertrophy n vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1): E125–32.
23. Kong J, Qiao G, Zhang Z, Liu SQ, Li YC. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008;74(12):1577–81. doi:10.1038/ki.2008.452
24. Li YC, Qiao GL, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the reninangiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89–90(1–5):387–92.
25. Kristal-Bneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension. 1997;30(5):1289–94.
26. Sowers M, Wallace R, Hollis B, Lemke JH. Relationship between 1,25-dihydroxyvitamin D and blood pressure in a geographically defined population. Am J Clin Nutr. 1988;48 (4):1053–6.
27. Schluter KD, Piper HM. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol. 1992;263(6 Pt 2): H1739–46.
28. Perkovic V, Hewitson TD, Kelynack KJ, Martic M, Tait MG, Becker GJ. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res. 2003;26 (1):27–33.
29. Martin-Ventura JL, Ortego M, Esbrit P, HernándezPresa MA, Ortega L, Egido J. Possible role of parathyroid hormonerelated protein as a proinflammatory cytokine in atherosclerosis. Stroke. 2003;34(7):1783–9.
30. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–56.
31. Bid HK, Mishra DK, Mittal RD. Vitamin-D receptor (VDR) gene (Fok-I, Taq-I and Apa-I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Prev. 2005;6 (2):147–52.
32. Dilmec F, Uzer E, Akkafa F, Kose E, van Kuilenburg AB. Detection of VDR gene ApaI and TaqI polymorphisms in patients with type 2 diabetes mellitus using PCR-RFLP method in a Turkish population. J Diabetes Complications. 2010;24(3):186–91. doi:10. 1016/j.jdiacomp.2008.12.002
33. Testa A, Mallamaci F, Benedetto FA, Pisano A, Tripepi G, Malatino L et al. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progressionin end-storage renal disease (ESRD) patients. J Bone Mineral Res. 2010;25(2):313–9. doi:10.1359/jbmr.090717
34. El-Shebany EM, El-Khatib MM, Marzouk S, Battah AA. Relationship of BsmI polymorphism of Vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. Scandinavian J of Clin And Lab Invest. 2013;73(1):75–81. doi:10.3109/00365513.2012.743163
35. Santoro D, Gagliostro G, Alibrandi A, Ientile R, Bellinghieri G, Savica V et al. Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease. Nutrients. 2014;6(3):1029–37. doi:10.3390/nu6031029
36. Solak Y, Covic A, Kanbay M. What do we know and do not know about vitamin D? A causal association between vitamin D receptor genetic polymorphism and hypertension. J Clin Hypertens. 2014;16(9):627–8. doi:10.1111/jch.12383
37. Muray S, Parisi E, Cardús A, Craver L, Fernández E. Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J Hypertens. 2003;21(11):2069–75.
38. Swapna N, Vamsi UM, Usha G, Padma T. Risk conferred by FokI polymorphism of vitamin D Receptor (VDR) gene for essential hypertension. Indian J Hum Genet. 2011;17(3):201–6. doi:10.4103/0971–6866.92104
39. Lee BK, Lee GS, Stewart WF, Ahn KD, Simon D, Kelsey KT et al. Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and deltaaminolevulinic acid dehydratase genes. Environ Health Perspect. 2001;109(4):383–9.
40. Kulah E, Dursun A, Acikgoz S, Can M, Kargi S, Ilikhan S et al. The relationship of target organ damage and 24-hour ambulatory blood pressure monitoring with vitamin D receptor gene Fok-I polymorphism in essential hypertension. Kidney and Blood Pressure Research. 2006;29(6):344–50.
41. Wang L, Ma J, Manson JE, Buring JE, Gaziano JM, Sesso HD. A prospective study of plasma vitamin D metabolites, vitamin D receptor gene polymorphism, and risk of hypertension in men. European J of Nutrition. 2013;52 (7):1771–9. doi:10.1007/s00394– 012–0480–8
42. Andrukhova O, Slavic S, Zeitz U, Riesen SC, Heppelmann MS, Ambrisko TD et al. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol. 2014;28(1):53–64. doi:10.1210/me.2013–1252
43. Каронова Т. Л, Баженова Е. А, Беляева О. Д, Березина А. В, Иванова Т. Г, Галкина О. В. и др. Роль дефицита витамина D в формировании артериальной гипертензии. Артериальная гипертензия. 2015;21(4):348–55..
44. Жидулева Е. В., Иртюга О. Б., Муртазалиева П. М., Каронова Т. Л., Моисеева О. М. Биомаркеры костного метаболизма при аортальном стенозе: роль дефицита витамина D. Российский кардиологический журнал. 2016;11(139):54–9. doi:10.15829/1560–4071–2016–11–54–59..
45. Каронова Т. Л. Метаболические и молекулярногенетические аспекты обмена витамина D и риск сердечнососудистых заболеваний у женщин: автореф. дис. … д-ра мед. наук: 14.01.05, 14.01.02. 2014;36..
46. Gunta SS, Thadhani RI, Mak RH. The effect of vitamin D status on risk factors for cardiovascular disease. Nature Reviews Nephrology. 2013;9(6):337–47. doi:10.1038/nrneph.2013.74
47. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D (3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86 (4):1633–7.
48. Scragg R, Slow S, Stewart AW, Jennings LC, Chambers ST, Priest PC et al. Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: a randomized controlled trial. Hypertension. 2014;64(4):725–30. doi:10.1161/HYPER- TENSIONAHA.114.03466
49. Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85(1):54–9.
50. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr. 2009;48(6):349–54. doi:10.1007/s00394–009–0020–3
51. Nagpal J, Pande JN, Bhartia AA. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med. 2009;26(1):19–27. doi:10.1111/j.1464–5491.2008.02636.x
52. Zittermann A, Frisch S, Berthold HK, Götting C, Kuhn J, Kleesiek K et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89(5):1321–7. doi:10.3945/ajcn.2008.27004
53. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women’s Health Initiative Randomized Trial. Hypertension. 2008;52(5):847–55. doi:10.1161/HYPERTENSIONAHA.108.114991
54. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009;27(10):1948–54. doi:10.1097/HJH.0b013e32832f075b
55. Witham MD, Adams F, Kabir G, Kennedy G, Belch JJ, Khan F. Effect of short-term vitamin D supplementation on markers of vascular health in South Asian women living in the UK: a randomized controlled trial. Atherosclerosis. 2013;230(2):293–9. doi:10.1016/j.atherosclerosis.2013.08.005
56. Arora P, Song Y, Dusek J, Plotnikoff G, Sabatine MS, Cheng S et al. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation. 2015;131(3): 254–62. doi:10.1161/CIRCULATIONAHA.114.011732
57. Pilz S, Gaksch M, Kienreich K, Grübler M, Verheyen N, Fahrleitner-Pammer et al. Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension. 2015;65(6):1195–201. doi:10.1161/HYPERTEN- SIONAHA.115.05319